Terms: = Endocrine gland cancer AND ER, estrogen receptor AND Treatment
596 results:
1. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract] [Full Text] [Related]
2. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study.
Man Q; Pang H; Liang Y; Chang S; Wang J; Gao S
Medicine (Baltimore); 2024 Mar; 103(10):e37440. PubMed ID: 38457597
[TBL] [Abstract] [Full Text] [Related]
3. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
4. Unfolded Protein-Based Sandwich AIE Probe Imparts High Fluorescent Contrast for Pan-cancer Surgical Navigation.
Wang Q; Chen B; Duan C; Wang T; Lou X; Dai J; Xia F
Anal Chem; 2024 Feb; 96(8):3609-3617. PubMed ID: 38364862
[TBL] [Abstract] [Full Text] [Related]
5. AURKA Enhances the Glycolysis and Development of Ovarian Endometriosis Through ERβ.
Sun Y; Zhang S; Zhang X; Li G; Sun F; Wang M; Ren C; Jiang A; Yang T
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38340326
[TBL] [Abstract] [Full Text] [Related]
6. Effects of postoperative antioxidants on the salivary glands in patients with thyroid cancer undergoing radioactive iodine-131 treatment.
Tong H; Yue R; Fang J; Li X; Yang S; Hou Y; Wang R; Zhang B; Liu H; Wu Z; Cheng Y
Nucl Med Commun; 2024 Apr; 45(4):312-320. PubMed ID: 38312062
[TBL] [Abstract] [Full Text] [Related]
7. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
8. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract] [Full Text] [Related]
9. Long-Term Follow-Up of Tamoxifen treatment and the Use of Imaging in Psammocarcinoma: A Case Report, Review of the Literature and Discussion of Diagnostic and Therapeutic Challenges.
Gideonsson I; Israelsson P; Strandberg SN; Ottander U
Curr Oncol; 2023 Nov; 30(12):10260-10271. PubMed ID: 38132381
[TBL] [Abstract] [Full Text] [Related]
10. Pan-Inhibition of Protein Disulfide Isomerase Caused Cell Death through Disrupting Cellular Proteostasis in Pancreatic Ductal Adenocarcinoma Cells.
Hung CS; Lee KL; Huang WJ; Su FH; Liang YC
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003657
[TBL] [Abstract] [Full Text] [Related]
11. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
12. An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.
Li CY; Chou TF; Lo YL
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127905. PubMed ID: 37939778
[TBL] [Abstract] [Full Text] [Related]
13. Integrated treatment guided by RNA-seq-based endometrial receptivity assessment for infertility complicated by MEN1.
Huang X; Fu J; Zhang Q; Zhao J; Yao Z; Xia Q; Tang H; Xu A; He A; Liang S; Lu S; Li Y
Front Endocrinol (Lausanne); 2023; 14():1224574. PubMed ID: 37929040
[TBL] [Abstract] [Full Text] [Related]
14. Apoptotic Effect of Gallic Acid via Regulation of p-p38 and ER Stress in PANC-1 and MIA PaCa-2 Cells Pancreatic cancer Cells.
Kim JW; Choi J; Park MN; Kim B
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894916
[TBL] [Abstract] [Full Text] [Related]
15. cancer stemness kinase inhibitor amcasertib: a promising therapeutic agent in ovarian cancer stem and cancer cell models with different genetic profiles.
Guler Kara H; Ozates NP; Asik A; Gunduz C
Med Oncol; 2023 Oct; 40(12):342. PubMed ID: 37891391
[TBL] [Abstract] [Full Text] [Related]
16. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.
Gambale C; Prete A; Contartese L; Torregrossa L; Bianchi F; Molinaro E; Materazzi G; Elisei R; Matrone A
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855417
[TBL] [Abstract] [Full Text] [Related]
17. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
18. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract] [Full Text] [Related]
19. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
[TBL] [Abstract] [Full Text] [Related]
20. Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma.
Karatug Kacar A
Chem Biol Drug Des; 2024 Jan; 103(1):e14368. PubMed ID: 37802653
[TBL] [Abstract] [Full Text] [Related]
[Next]
